Patents by Inventor Michael W. Cappi

Michael W. Cappi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS
    Publication number: 20150336992
    Abstract: The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:
    Type: Application
    Filed: August 3, 2015
    Publication date: November 26, 2015
    Inventors: Christian Hubschwerlen, Jean-Luc Specklin, Daniel Baeschlin, Christine Schmitt, Stefan Müller, Michael W. Cappi
  • Oxazolidinone-quinolone hybrid antibiotics
    Patent number: 9133213
    Abstract: The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: September 15, 2015
    Assignee: Morphochem Aktiengesellschaft Für Kombinatorische Chemie
    Inventors: Christian Hubschwerlen, Jean-Luc Specklin, Daniel Baeschlin, Christine Schmitt, Stefan Müller, Michael W. Cappi
  • OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS
    Publication number: 20130296275
    Abstract: The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:
    Type: Application
    Filed: July 2, 2013
    Publication date: November 7, 2013
    Inventors: Christian Hubschwerlen, Jean-Luc Specklin, Daniel Baeschlin, Christine Schmitt, Stefan Müller, Michael W. Cappi
  • Oxazolidinone-quinolone hybrid antibiotics
    Patent number: 8501774
    Abstract: The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: August 6, 2013
    Assignee: Morphochem Aktiengesellschaft für Kombinatorische Chemie
    Inventors: Christian Hubschwerlen, Jean-Luc Specklin, Daniel Baeschlin, Christine Schmitt, Stefan Muller, Michael W. Cappi
  • OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS
    Publication number: 20120142635
    Abstract: The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:
    Type: Application
    Filed: February 8, 2012
    Publication date: June 7, 2012
    Applicant: Morphochem Aktiengesellschaft Fur Kombinatorische Chemie
    Inventors: Christian Hubschwerlen, Jean-Luc Specklin, Daniel Baeschlin, Christine Schmitt, Stefan Müller, Michael W. Cappi
  • Oxazolidinone-quinolone hybrid antibiotics
    Patent number: 8158797
    Abstract: The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria.
    Type: Grant
    Filed: December 20, 2004
    Date of Patent: April 17, 2012
    Assignee: Morphochem Aktiengesellschaft fur Kombinatorische Chemie
    Inventors: Christian Hubschwerlen, Jean-Luc Specklin, Daniel Baeschlin, Christine Schmitt, Stefan Müller, Michael W. Cappi
  • 5-Quinoline derivatives having an anti-bacterial activity
    Publication number: 20100324030
    Abstract: The present invention describes novel anti-bacterial compounds of the formula (I). These compounds are, amongst others, of interest as inhibitors of DNA gyrase and topoisomerases, for example of topoisomerase II and IV.
    Type: Application
    Filed: April 11, 2008
    Publication date: December 23, 2010
    Applicant: Morphochem Aktiengesellschaft Fur Kombinatorische Chemie
    Inventors: Glenn Dale, Sabine Pierau, Michael W. Cappi, Christopher Gray, Christian Hubschwerlen, Jean P. Surivet, Cornelia Zumbrunn
  • Macrocycles for the treatment of cancer
    Patent number: 7807710
    Abstract: The invention relates to the novel macrocycles of general formula (I) and to their use in the treatment of tumor diseases.
    Type: Grant
    Filed: September 27, 2004
    Date of Patent: October 5, 2010
    Assignee: R&D-Biopharmaceuticals GmbH
    Inventors: Wolfgang Richter, Bernd Henkel, Michael W. Cappi
  • Oxazolidinone-Quinolone Hybrid Antibiotics
    Publication number: 20080027040
    Abstract: The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:
    Type: Application
    Filed: December 20, 2004
    Publication date: January 31, 2008
    Applicant: Morphochem Aktiengesellschaft Fur Kombinatorische
    Inventors: Christian Hubschwerlen, Jean-Luc Specklin, Daniel Baeschlin, Christine Schmitt, Stefan Muller, Michael W. Cappi
  • Compounds that inhibit factor Xa activity
    Patent number: 6794507
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, hydrate or a pharmaceutically acceptable formulation thereof. Those compounds can be used for inhibiting factor Xa and for the prevention and/or treatment of thromboembolic conditions.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: September 21, 2004
    Assignee: Morphochem AG
    Inventors: Michael W. Cappi, Thilo Fuchs, Robert Eckl, Silke Schabbert
  • Novel compounds inhibiting factor xa activity
    Publication number: 20030153510
    Abstract: The present invention relates to compounds of formula (I): 1
    Type: Application
    Filed: February 19, 2003
    Publication date: August 14, 2003
    Inventors: Michael W Cappi, Thilo Fuchs, Robert Eckl, Silke Schabbert
  • Use of particular compounds for prophylaxis and treatment of hepatitis c
    Publication number: 20030153594
    Abstract: The present invention relates to the use of a compound of formula (I): 1
    Type: Application
    Filed: November 12, 2002
    Publication date: August 14, 2003
    Inventors: Lutz Webber, Sven Nerdinger, Michael W Cappi, Dirk Behnke